secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0000950170-23-000597
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reaffirms FY2022 net loss guidance of $245M–$265M
----------------------------------------------------------------------

- Net loss expected to be between $245M and $265M for the year ended December 31, 2022.
- Includes estimated non-cash stock-based compensation of approximately $30M to $35M.
- Company also posted a corporate presentation on January 10, 2023, covering its R&D pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/0000950170-23-000597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/rvmd-20230110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer